RxDoctor Payments Data

Mansi Patel

Family · Waukesha, WINPI 1720677925

Payments from drug & device makers

$568in general payments, 2019–2025

Across 24 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$122
  • Gilead$107
  • Vanda Pharmaceuticals Inc.$52
  • Neurocrine Biosciences, Inc.$42
  • Takeda Pharmaceuticals U.S.A., Inc.$40
  • Lilly USA, LLC$31
  • plus $174 from 8 others

What the payments were for

  • Food & beverage$568100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$568 in reported general payments places this provider in the 75th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$85,326
Medicare patients
157
Services billed
1,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$15,570
JardianceEmpagliflozin17$7,032
EntrestoSacubitril/Valsartan13$5,049
Gabapentin94$2,523
Aripiprazole21$2,240
Carbamazepine ErCarbamazepine13$2,176
Tramadol Hcl43$1,077
Pantoprazole Sodium48$1,009
Lamotrigine29$817
Bumetanide26$759
Atorvastatin Calcium54$702
Levothyroxine Sodium51$649
Amlodipine Besylate58$635
Oxycodone Hcl39$633
Famotidine24$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$15,57028 claims
Lilly USA, LLCOlanzapine$31$37313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,273 family providers in Wisconsin.

Other family in Waukesha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →